Compare NXRT & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXRT | PRME |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.4M | 526.0M |
| IPO Year | 2014 | 2022 |
| Metric | NXRT | PRME |
|---|---|---|
| Price | $17.70 | $5.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $25.25 | $7.11 |
| AVG Volume (30 Days) | 519.3K | ★ 4.7M |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | ★ 11.54% | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,281,000.00 | $4,632,000.00 |
| Revenue This Year | $2.06 | $90.65 |
| Revenue Next Year | $2.37 | $19.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $17.67 | $2.67 |
| 52 Week High | $32.36 | $5.03 |
| Indicator | NXRT | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 72.52 |
| Support Level | N/A | $2.89 |
| Resistance Level | $20.22 | N/A |
| Average True Range (ATR) | 0.66 | 0.43 |
| MACD | 0.10 | 0.13 |
| Stochastic Oscillator | 8.31 | 98.67 |
NexPoint Residential Trust Inc is a real estate investment trust company. The trust's objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.